Lovenox
(Enoxaparin sodium)Phase 3Small molecule
SanofiEnoxaparin is a blood thinner used to prevent and treat blood clots, particularly in the legs and lungs, and to reduce the risk of clotting in patients undergoing surgery or those with heart conditions.[1] Lovenox is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]
Lovenox is one of 392 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.
17
Indications
33
Total Trials
4
Active Trials
391
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Lovenox
SanofiPhase 3
Spikevax
ModernaPreclinical
Stivarga
BayerPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Orap
TevaPreclinical
Calcium
Eli LillyPreclinical
Conventional
PPopulation Health Research Institute
Preclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Venous Thromboembolism6 trials
Show 3 more trials
Total Knee Arthroplasty4 trials
A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Active, not recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 3·NCT06825416·1,166 enrolled
Enoxaparin3 trials
Thromboembolism2 trials
15 more indications
Total Hip Arthroplasty2 trials
Acute Coronary Syndrome1 trial
Fasting Conditions1 trial
Prophylaxis1 trial
PK/PD1 trial
Small Cell Lung Cancer1 trial
Effectiveness1 trial
Adult Subject1 trial
Chemotherapy1 trial
Venous thrombosis1 trial
Acute Myocardial Infarction1 trial
Spinal Cord Injury1 trial
Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
Recruiting·—·N/A·NCT05484557·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enoxaparin sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]